Schizophrenia Flashcards by Raphaella Ridley

Delay and Deniker

o The chance observation that chlorpromazine induced a calming effect initiated a remarkable period of efficacious therapy
o In France, chlorpromazine was being tried as an anaesthesia adjunct that might prevent shock or have beneficial properties
o Chosen as the least sedative of the antihistamines available at the time, it was tested in a wide variety of patients
o When tried in patients with SCZ, Delay and Deniker reported their results at a psychiatric meeting in Luxemburg and then very quickly in a journal article in 1952 describing spectacular results in acutely psychotic SCZ pts

How well did you know this?

Not at all

Perfectly

Wright (2000)

Found a number of changes e.g. ventricular enlargement, decreased cortical, grey matter, hippocampal+thalamic volume + larger basal ganglia. Likewise, there is reduced blood flow to the globus pallidus and frontal lobes Overall, cerebral volume decreased by 3% but w careful sterotaxic counts it is seen that a higher density of neurons remains in this volume (no real change in number of neurons so brain is more densely populated - strange!)

How well did you know this?

Not at all

Perfectly

Moncrieff and Leo (2010)

SR of MRI studies looking at the role of antipsychotic medication onstructural changes found decreased grey matter and increased ventricular volume associated w antipsychotic treatment; limited changes in drug-naïve pts 14 of 26 longitudinal studies showed a decline in global brain or grey matter volume or an increase in ventricular or CSF volume during the course of drug treatment some evidence points towards the possibility that antipsychotic drugs reduce the volume of brain matter and increase ventricular fluid volume, ANTIPSYCHOTICS MAY CONTRIBUTE TO THE GENESIS OF SOME OF THE ABNORMALITIES USUALLY ATTRIBUTED TO SCHIZOPHRENIA

How well did you know this?

Not at all

Perfectly

Connel 1957

published a series of case reports showing amphetamines, which cause DA release, induce psychotic symptoms akin to SCZ positive symptoms

APs (indeed all currently licensed) reduce DA transmission and inhibit positive symptoms of DA in ~70% of pts

How well did you know this?

Not at all

Perfectly

Angrist et al 1970

Looked at effects of amphetamine in 4 healthy subjects. Lead to hallucinations and delusions. Known to increase DA

amphetamine also increases NA and 5-HT, participants were experienced amphetamine users - might have neurophysiological/chemical changes in brain

How well did you know this?

Not at all

Perfectly

Johnstone 1978

clinical trial compared AP drug alpha-flupenthixol vs placebo and against beta-flupenthixol (optical isomer which does not bind to D2R), which was more efficacious than control and isomer, demonstrating necessity of DR2 blockage

How well did you know this?

Not at all

Perfectly

Seeman 1976

They used PET. Measured 3H haloperidol conc before/after addition of different APs. Plotted DAR affinity (ability to displace haloperidol) with clinical dose needed for efficacy, finding a strong correlation between efficacy of APs and affinity for D2 receptors

Was in vitro - does this apply in vivo?

How well did you know this?

Not at all

Perfectly

Howes 2013

18F-DOPA (radiolabelled DOPA) in PET of AP-free SCZ, increased DOPA uptake in striatal neurons, w extent of uptake correlating w the severity of symptoms (key finding), and elevated in pts w prodromal psychotic symptoms (before onset of disease), and further elevated w onset of acute psychosis

How well did you know this?

Not at all

Perfectly

Volkow 1999

11C raclopride has D3 binding. Amphetamine-induced DA release is not a physiologically similar situation to SCZ, and argued that effect could have been due to differences in amphetamine metabolism or its ability to enter the CNS - it is artificial - how much can you read into this? A

How well did you know this?

Not at all

Perfectly

Abi-Dargham 2000

used SPECT with [123I]-IBZM to measure baseline dopamine occupancy of D2 receptors. o Schizophrenic patients and control subjects were administered alpha-methyl-para-tyrosine (TH inhibitor) to deplete endogenous dopamine. The decrease in receptor occupancy was significantly greater for schizophrenic patients (19% compared to 9%), indicating greater receptor occupancy at baseline, which supports the mesolimbic hyperdopaminergic theory of schizophrenia.

Assumes the magnitude of DA depletion is the same between SCZ and ctrl

How well did you know this?

Not at all

Perfectly

Howes et al. 2012

meta-analysis of 44 in vivo studies with 600 pts and 600 controls looking at striatal dopamine with PET “Around a doubling of synaptic DA, and of D2 R occupancy in pts compared to controls They found that there was a highly sig elevation in presynaptic dopaminergic function in SCZ (dopamine synthesis capacity, basline DA levels and dopamine release). These are not targeted by current drug treatments, which primarily act to block D2 Rs - fail to target these abnormalities. Need future drugs to focus on the control ofpresynaptic DA synthesis and release capacity”

How well did you know this?

Not at all

Perfectly

Abi-Dargham 2002

PET study measuring selective D1 receptor availability with labelled D1 antagonist. confirmed D1R increased throughout cortex in SCZ, only statistically sig difference was in dorsolateral PFC; thought to be increased as compensatory phenomenon due to DA deficit. May be that this upregulation is not functional due to lack of stimulation by endogenous DA and so PFC-mediated deficits (underlying negative + cognitive symptoms)

How well did you know this?

Not at all

Perfectly

Slifstein et al. 2015

PET has only recently become sensitive enough to detect PFC DA alterations. This is the first in vivo example of this. They looked a 20 schizophrenics and 20 controls. They did PET imaging using 11[C]-GLB457 radiotracer which binds to both D2 and D3 receptors. They gave a bolus of amphetamine to each group (for DA release). Demonstrate that DA release is significantly reduced in DL PFC of SCZ.

How well did you know this?

Not at all

Perfectly

Egan 2001

They looked at COMT (enzyme involved in DA degradation) – specifically a common functional polymorphism, that accounts for 4-fold variation in enzyme activity and dopamine catabolism. Compared the presence of this to performance on Wisconsin Card Sorting test of executive function in 175 SCZ, 219 unaffected siblings, 55 controls. Found the genotype explained 4% of variance of WCS score (p=0.001); low activity Met allele predicted enhanced cognitive performance. Then examined COMT genotype on physiological PFC response using fMRI and Met allele predicted more efficient physiological response in PFC. They did a family-based association analysis and found that there was significant transmission of the Val allele to SCZ offspring (not the met allele) o So overall more COMT activity = more prefrontal DA catabolism = worse WCS score (impaired prefrontal cognition) and reduced PFC signalling (= means association with)

How well did you know this?

Not at all

Perfectly

Kellendonk et al 2006

generated transgenic mouse model in which D2R expression could be selectively upregulated in the striatum, mimicking DA hyperactivity
Mice had decreased DA turnover in the PFC, and performed poorly in PFC-dependent cognitive tasks that persisted even long after the transgene had been turned off
Also get D1R upregulation in these mice, as PET studies in humans SCZs show you do, but limited D1R antagonist trials show lack of efficacy or symptoms worsening
Idea that excessive DA during development somehow causes cortical DA insufficiency and cognitive deficit, hence D2R antagonist in early adulthood have no effect on cognitive or negative symptoms

Limitations

No direct link to cog deficits (could have used opto/chemgen to activate/inhibit). Also going from one transgenic mouse model to this is the core pathology of SCZ - bit of a leap.

How well did you know this?

Not at all

Perfectly

Carlsson et al 2006

Came up with DA deficit hypothesis

How well did you know this?

Not at all

Perfectly

Kapur 2003

Came up w aberrant salience theory

How well did you know this?

Not at all

Perfectly

Olney and Farber 1995

put forward first NMDAR dysfunction hypothesis of SCZ, showing that animals given NMDAR antagonists developed neurotoxic changes in cortical brain regions, which they suggested were similar to reduction in brain volume seen in pts w SCZ. AMPAR antagonists could block downstream effects of NMDAR antagonist on neurotoxicity, hypothesising that glutamate release might underlie neurotoxic effects

How well did you know this?

Not at all

Perfectly

Moghaddam et al. 1997

confirmed this w microdialysis of healthy rats w subanaesthetic doses of ketamine, which they found increased extracellular glutamate in the PFC and found that this also impaired cognitive functions and produced motor sterotypy. This increase in extracellular glutamate had functional significance because blockade of AMPA receptors reduced these motoric and cognitive detriments of NMDAR blockade. Therefore, NMDA antagonsits appeared to increase glutamate release at some synapses which then abnormally increased glutamate neurotransmission at non-NMDAR, in particular AMPA receptors. These results suggests that the behavioural conseqeucnes of NMDAR deficiency is not due to a generalised glutamate hypofunction but dysregulation of glutamate neurotransmission that may involve NMDAR hypofunciton and excessive activity of non-NMDA receptors

How well did you know this?

Not at all

Perfectly

Moghaddam 98

General animal model stuff (stereotypy not scz), furthermore, although in 2007 clinical trial mGlu2/3 agonists were shown to improve both positive and negative symtpoms, future trials have failed to show effect - maybe its to do with different subcategories of scz?

How well did you know this?

Not at all

Perfectly

Krystal 1994

19pts. Given either placebo or 2 doses of K (0.1&0.5mg/kg). Produced behaviours similar to + and - symptoms (e.g. increases in hallucinations nand impaired in WCST so frontal dysfunction)

Recruitment through adverstising (homogenous population), not causal, ketamine is short-term but scz develops over a long period of time - different mechanisms?

How well did you know this?

Not at all

Perfectly

mGlu2/3 agonists

Patil 2007 - phase II clinical trial - mGlu2/3 agonists were shown to improve both positive and negative symtpoms, future phase III trials have failed to show effect - maybe its to do with different subcategories of scz? Was only assessed for 4 weeks - AP drugs would need longer.Liu 2012 later showed that this agonist was only effective in pts with a specific SNP in the 5-HT2A receptor - although this second one was candidate gene approach (picked genes to investigate depending on their association with the pharmacological action) - maybe there is even more subcategorisation?

How well did you know this?

Not at all

Perfectly

Mohn 1999

Maybe microdialysis at the time was not specific enough to pick up the D, could have used FSCV. Havent seen NR1 in GWAS. Used a homologus recombination technique which could lead to ectopic recombination in other places. Did global NDMA hypofuction, rather than in specific circuits. The mice also showed autism-related behaviooural deficits (maybe not representative of scz)

How well did you know this?

Not at all

Perfectly

Belforte et al. 2010

Direct SCZ-related symptoms emerged after adolescence (including 1 novelty-induced hyperlocomotion, 2 mating and nest-building deficits, and 3 anhedonia-like and 4 anxiety-like behaviours). Also showed reduction in GAD67 - potential reduction in GABA synthesis - reduction in GABAergic inhibition - cortical disinhibition

not affected à neurodevelopmental hypothesis. Idea that early postnatal inhibition of NMDAR activity could contribute to pathophysiology of SCZ. Also no GAD67 reduction. Early postnatal NMDAR hypofunction in GABAergic IN is needed for SCZ-like behaviour

Limitations

1) Lack of consensus on altered subunit levels in post-mortem brain studies, so hard to ascertain construct validity (also in genetics), 2) based on expression of behavioural analogues for SCZ in humans, 3) which subtupe of GABA IN? 3) do both cortical and hippocampal INs play a role? (both were targetted), 4) only 50% of INs were even targetted

How well did you know this?

Not at all

Perfectly

Maher 2012

Tsai and Lin 2010

meta-analysis of NMDAR-modifying drugs. Looked at about 800 subjects from 26 studies. Showed these significantly improves positive + negative and cognitive symptoms when administered in addition to existing AP treatment

Bartha et al 1997

Proton magnetic resonance spectroscopy of 10 SCZ and 10 controls – found sig increased glutamine levels in medial PFC of SCZ compared to controls

Bustillo et al. 2014

MRS. found that chronic SCZ pts have elevated glutamine levels in anterior cingulate cortex compared to healthy controls. The levels of glutamine also positively correlated with the severity of positive symptoms Cav- 1H-MRS doesn’t distinguish IC vs EC - cant see if glutamate has actually been released. Cant tell if this is a cause or a consequence of the disease

Flames et al 2004

"o In E13.5 medial ganglionic eminence (MGE)/cortex in vitro co-cultures, neurons from the MGE migrated towards the cortex (what happens in development) o However, MGE neurons electroporated (increase the permeability of the cell membrane with an electrical field) with dominant-negative ErbB4 became largely unresponsive to the cortical attractant. (basically if you lose Erb4, you lose this migration) o They also created ErbB4 mouse mutants expressing ErbB4 under a cardiac-specific myosin promoter to avoid embryonic lethality due to failure of myocardial trabeculae formation. o IHC for calbindin, a marker of migrating GABAergic INs, revealed sig fewer migratinc cortical INs in those mice compared to controls" ErbB4 had previously been implicated in susceptibility to scz - this just shows that GABAergic IN migration may be affected by this

Steinecke et al 2012

electroporated MGE cells in embryonic mouse brain w anti-DISC1 miRNA to cause DISC1 RNAi, + Alexa 546 to visualise transfected cells (in control animals only the latter was transfected). RNAi of DISC1 sig reduced the no of neurons migrating tangentially to the cortex

Volk et al 2000

They performed ISH on tissue sections from 10 pairs of subjects (SCZ + healthy controls) w sulphur-35-labelled oligonucleotide probes. They found sig decreased density of GAD67 (GABAergic interneuron marker) labelled neurons in subjects w SCZ. However, a sig limitation of this study was the small sample size. Therefore, developmental defects in GABAergic IN migration may contribute to GABAergic PFC hypofunction, so increase risk of SCZ.

The Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014

GWAS, 37,000 patients and 113,000 controls. Identified 600 genes associated with SCZ, 83 of which were newly implicated Incl DRD2 many w NMDA CACNA1A and CACNA2B Some involved in immunity - immune enhancers (CD20 B lymphocytes e.g.) MHC = strongest association

Sekar 2016

"C4 exists as two functionally distinct genes - C4A and C4B - these vary in structure and copy number. They assessed how C4 variation related to RNA expression of C4A and C4B in post mortem human adult brain samples. Found that each C4 allele was associated with schizophrenia risk in proportion to its effect on C4A expression. o Using IHC, and high-resolution structured illumination microscopy imaging, they determined that neuronal dendrites, axons and synapses expressed C4. For example, it co-localises w presynaptic markers VGLUT1/2 and postsynaptic marker PSD-95 o C4 was then shown to promote synapse elimination in mice during the developmentally timed maturation of a neuronal circuit"

Li et al 2007

Looked at the CA3-CA1 pathway in hippocampal slices - transduction of CA1 neurons with lentivirus expressing shRNAs, producing RNAi knockdown of ErbB4, or the addition of the ErbB4 antagonsit AG1478 significantly depressed NMDAR-mediated synaptic tranmission (whole cell postsynaptic patch clamp recordings) ErB4/NGR1 impairment leads to NMDAR dysfunction

Hikida 2007

Generated mice with truncated form of Disc1 under the control of promoter aCaMKII which drived gene expression in forebrain neurons Show enlarged lateral ventricles and decreased numbers of interneurons, hyperactivity, impaired PPI, increased immobililty in FST, social interactions, or spatial memory

Kim et al 2021

Found that phosphodiesterase 4 (PDE4) transcripts are elevated in neurons differentiated from iPSCs with the DISC mutation (RNA seq) Pharma inhibition of PDE4 or or cAMP activation rescues synaptic deficits Mouse knock in with same DISC1 mutation had elevated PDE4 and synaptic abnormalities and SCZ-like behaviour (was heterozygous KI so some DISC1 = normal) Inhibition of PDE4 rescued synaptic abnormalities and behaviour Could present a future drug target - however, PDE4 is ubiquitous - could we really target it?

Singh et al April 2022

* Described 10 robust rare varients in MA of whole exomes of 24,000 cases and 97,000 controls. * Identified 10 ultra-rare coding variants in 10 genes conferring substantial risk for SCZ. * These had diverse molecular functions including the formation, structure and function of the synapse. * Protein truncating varients of GRIN2A, TRIO and CACNA1G are examples of genes implicated * GRIN2A = NMDA receptor subunit = glutamatergic * Showed for the first time that commonly regulatory variants from GWAs and ultra-rare coding variants disrupt an overlapping set of genes. Gives confidence that integration of results from sequencing consortia with GWAS efforts will have significant value for identifying specific genes beyond what any strategy can achieve on its own - GRIN2A was in this overlap * There was also overlap in rare variant risk w autism, epilepsy and severe neurodevelopmental disorders - supports neurodevelopmental hypothesis

Schizophrenia Working Groups of the Pyschiatric Genomics Consortium 2017

meta-analysis incorporating over 21,000 SCZ cases and 20,000 controls looking at CNVs Generated definitive evidence for 8 loci - they suggest that these are carried by 1.4% of SCZ

Bernnand 2011

directly reprogramming SCZ pt fibroblasts into HiPSCs and then differentiated these into neurons Using trans-neuronal spread of rabies virus (stronger synapse = better spread) as an assay of neuronal connectivity, they found this was decreased in these neyrons Does not necessarily mean synaptic function is decreased (could be limitations fo synaptic activity assays)" " Decreased number of neurites (in keeping with SCZ post-mortem and animal models), decreased PSD95 expression relative to MAP2AB but not to signifiance, and decreased glutamate R expression - Spontaneous neuronal activity unaffected" - Almost 600 genes had expression altered more than 1.3-fold, 25% had been previously implicated in SCZ sig alterations in glutamate, cAMP and WNT signalling, needed for activity-dependent refinement of synaptic connections and LTP " her APs did nto but could be dosing needs optimisation" - Data support idea of CZ model where many different combinations of gene dysfunction may disrupt the key pathways affected in SCZ. Increase number of hiPSC cases and see consistent genes affected, and essential pathways will come to light

Demhaja et al 2014

Treatment resistant SCZ shown to have normal 18F-DOPA uptake in PET studies (and normal ACC glutamate), as opposed to SCZ pts who respond to APs and have elevated 18F-DOPA uptake (and normal ACC glutamate) Are the differences between glu and DA a cause or consequence of poor AP response?

Kim et al 2021

* Found that phosphodiesterase 4 (PDE4) transcripts are elevated in neurons differentiated from iPSCs with the DISC mutation (RNA seq) * Pharma inhibition of PDE4 or or cAMP activation rescues synaptic deficits * Mouse knock in with same DISC1 mutation had elevated PDE4 and synaptic abnormalities and SCZ-like behaviour (was heterozygous KI so some DISC1 = normal) * Inhibition of PDE4 rescued synaptic abnormalities and behaviour * Could present a future drug target - however, PDE4 is ubiquitous - could we really target it?

Schmack et al 2021

Designed behavioural sensory detection task in mice * Given tones embedded in white noise. Would poke a port if signal was there and another if it wasnt. Given water reward * Uncertainty was introduced by presenting auditory signals hardly distinguishable from the noise * Their confidence in the choices determined by time willing to wait for the reward after a response - behavioural proxy for confidence * Hallucination = high confidence false alarm (incorrect reports) (HALIP) Results * Increasing signal expectation by increasing proportion of signal to no signal trial = increased HALIPs * Administration of ket increased HALIP rate in mice They then devised a computational model * Explains these mouse 'hallucinations' as a consequence of more weight being put on prior expectation than sensory evidence. * Their model clarifies how these 'hallucinations' come from fluctuations in two different types of expection - reward expectations (DA fluctuation in v striatum) and perceptual expectations (DA fluctuation in tail of striatum) Used genetically encoded DA responses with fibre photometry to monitor DA dynamics * Found sustained increase of DA in the striatum in no-signal trials that preceded false alarm responses * Optogenetic stimulation of DA release in striatum lead to increased HALIPs * This was rescued with haloperidol Supports idea hallucinations come from elevated DA makes bias favouring expectations over sensory evidence Limitations * Time investments dont mean confidence (could just be learning to keep nose in for londer) * Didnt look at visual hallucinations etc * Did not investigate in a model of psychosis * Do not know if the neural processes underlying HALIPs overlap those that produce spontaneous hallucination sin scz Future * Human neuroimaging studies have shown how sound percepts are represented in the cortex during hallucinations. However, unclear how this auditory-related region of the striatum underpins this is unknown. Need deep-brain calcium imaging in large popultions of cortical and striatal neurons in animal models of hallucinations * Opens door to potential treatment - one study showed DBS of the humans striatum in tinnitus = reduction in loudness of tinnitus. Although Schmack gave haloperidol to reduce HALIPs, it remained unanswered if silencing striatal DA neurons is enough to prevent hallucinations

o The chance observation that chlorpromazine induced a calming effect initiated a remarkable period of efficacious therapy o In France, chlorpromazine was being tried as an anaesthesia adjunct that might prevent shock or have beneficial properties o Chosen as the least sedative of the antihistamines available at the time, it was tested in a wide variety of patients o When tried in patients with SCZ, Delay and Deniker reported their results at a psychiatric meeting in Luxemburg and then very quickly in a journal article in 1952 describing spectacular results in acutely psychotic SCZ pts

Delay and Deniker

Wright (2000)

Moncrieff and Leo (2010)

published a series of case reports showing amphetamines, which cause DA release, induce psychotic symptoms akin to SCZ positive symptoms APs (indeed all currently licensed) reduce DA transmission and inhibit positive symptoms of DA in ~70% of pts

Connel 1957

Looked at effects of amphetamine in 4 healthy subjects. Lead to hallucinations and delusions. Known to increase DA amphetamine also increases NA and 5-HT, participants were experienced amphetamine users - might have neurophysiological/chemical changes in brain

Angrist et al 1970

Johnstone 1978

Seeman 1976

Howes 2013

Used 11[C]-raclopride which binds D2Rs to measure amphetamine-induced DA release, fewer radiotracer-bound Rs in SCZ, demonstrating greater DA release. DA release increment correlated to aggravated psychosis 11C raclopride has D3 binding. Amphetamine-induced DA release is not a physiologically similar situation to SCZ, and argued that effect could have been due to differences in amphetamine metabolism or its ability to enter the CNS - it is artificial - how much can you read into this? A

Volkow 1999

Abi-Dargham 2000

meta-analysis of 44 in vivo studies with 600 pts and 600 controls looking at striatal dopamine with PET "Around a doubling of synaptic DA, and of D2 R occupancy in pts compared to controls They found that there was a highly sig elevation in presynaptic dopaminergic function in SCZ (dopamine synthesis capacity, basline DA levels and dopamine release). These are not targeted by current drug treatments, which primarily act to block D2 Rs - fail to target these abnormalities. Need future drugs to focus on the control ofpresynaptic DA synthesis and release capacity"

Howes et al. 2012

Abi-Dargham 2002

Slifstein et al. 2015

- Egan 2001

* generated transgenic mouse model in which D2R expression could be selectively upregulated in the striatum, mimicking DA hyperactivity * Mice had decreased DA turnover in the PFC, and performed poorly in PFC-dependent cognitive tasks that persisted even long after the transgene had been turned off * Also get D1R upregulation in these mice, as PET studies in humans SCZs show you do, but limited D1R antagonist trials show lack of efficacy or symptoms worsening * Idea that excessive DA during development somehow causes cortical DA insufficiency and cognitive deficit, hence D2R antagonist in early adulthood have no effect on cognitive or negative symptoms Limitations * No direct link to cog deficits (could have used opto/chemgen to activate/inhibit). Also going from one transgenic mouse model to this is the core pathology of SCZ - bit of a leap.

Kellendonk et al 2006

Came up with DA deficit hypothesis

Carlsson et al 2006

Came up w aberrant salience theory

Kapur 2003

Olney and Farber 1995

Moghaddam et al. 1997

Group II mGluRs are autoreceptors that inhibit glutamate release. They gave group II agonist prior to PCP (NMDA antagonist). Microdialysis = increase glutamate in PFC and motor sterotypy and decrease in cog performance. All reversed by the agonist and confirmed to not be reduced by a reduction in DA General animal model stuff (stereotypy not scz), furthermore, although in 2007 clinical trial mGlu2/3 agonists were shown to improve both positive and negative symtpoms, future trials have failed to show effect - maybe its to do with different subcategories of scz?

Moghaddam 98

19pts. Given either placebo or 2 doses of K (0.1&0.5mg/kg). Produced behaviours similar to + and - symptoms (e.g. increases in hallucinations nand impaired in WCST so frontal dysfunction) Recruitment through adverstising (homogenous population), not causal, ketamine is short-term but scz develops over a long period of time - different mechanisms?

Krystal 1994

mGlu2/3 agonists

Generated mice expressing only 5% of the normal levels of NR1 subunit of NMDA - survive to adulthood and display behavioural abnormalities, including increased motor activity and deficits in social and sexual interactions, similar to those seen in pharmcologically-induced animal models. These can be ameliorated through treatment with APs (cloz and halo). No changes in DA with microdialysis (only glutamate and not DA) Supports model where reduced NMDAR activity causes SCZ-like behaviour Maybe microdialysis at the time was not specific enough to pick up the D, could have used FSCV. Havent seen NR1 in GWAS. Used a homologus recombination technique which could lead to ectopic recombination in other places. Did global NDMA hypofuction, rather than in specific circuits. The mice also showed autism-related behaviooural deficits (maybe not representative of scz)

Mohn 1999

Built on previous studies (Mohn 99 in particular) .Transgenic mice using Cre-loxP, in which the essential NR1 subunit of the NMDAR was eliminated in 40-50% of cortical and hippocampal INs in early postnatal development. Direct SCZ-related symptoms emerged after adolescence (including 1 novelty-induced hyperlocomotion, 2 mating and nest-building deficits, and 3 anhedonia-like and 4 anxiety-like behaviours). Also showed reduction in GAD67 - potential reduction in GABA synthesis - reduction in GABAergic inhibition - cortical disinhibition not affected à neurodevelopmental hypothesis. Idea that early postnatal inhibition of NMDAR activity could contribute to pathophysiology of SCZ. Also no GAD67 reduction. Early postnatal NMDAR hypofunction in GABAergic IN is needed for SCZ-like behaviour Limitations 1) Lack of consensus on altered subunit levels in post-mortem brain studies, so hard to ascertain construct validity (also in genetics), 2) based on expression of behavioural analogues for SCZ in humans, 3) which subtupe of GABA IN? 3) do both cortical and hippocampal INs play a role? (both were targetted), 4) only 50% of INs were even targetted

- Belforte et al. 2010

showed this using optogenetics (light-sensitive channelrhodopsin-2 cation channel) to study glutamatergic release in light-stimulated wild-type and DISC1 knockdown neurons in a rodent model. o They found a significantly decreased glutamate release probability in DISC1-/- neurons, indicating the importance of DISC1 in presynaptic glutamate release. o DISC1 also binds to the presynaptic enzyme serine racemase, stabilising it. This is responsible for the production of D-serine, which acts as a coactivator of the NMDAR at the glycine modulatory site. o Therefore, reduction of DISC1 activity would also lead to reduced D-serine production, further contributing to NMDAR hypofunction.

Maher 2012

Tsai and Lin 2010

Proton magnetic resonance spectroscopy of 10 SCZ and 10 controls – found sig increased glutamine levels in medial PFC of SCZ compared to controls

Bartha et al 1997

Bustillo et al. 2014

Flames et al 2004

Steinecke et al 2012

Volk et al 2000

The Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014

Sekar 2016

Li et al 2007

Hikida 2007

Kim et al 2021

Singh et al April 2022

meta-analysis incorporating over 21,000 SCZ cases and 20,000 controls looking at CNVs Generated definitive evidence for 8 loci - they suggest that these are carried by 1.4% of SCZ

Schizophrenia Working Groups of the Pyschiatric Genomics Consortium 2017

directly reprogramming SCZ pt fibroblasts into HiPSCs and then differentiated these into neurons "Using trans-neuronal spread of rabies virus (stronger synapse = better spread) as an assay of neuronal connectivity, they found this was decreased in these neyrons o Does not necessarily mean synaptic function is decreased (could be limitations fo synaptic activity assays)" "Decreased number of neurites (in keeping with SCZ post-mortem and animal models), decreased PSD95 expression relative to MAP2AB but not to signifiance, and decreased glutamate R expression - Spontaneous neuronal activity unaffected" - Almost 600 genes had expression altered more than 1.3-fold, 25% had been previously implicated in SCZ sig alterations in glutamate, cAMP and WNT signalling, needed for activity-dependent refinement of synaptic connections and LTP "AP loxapine increased glutamate R expression and increased NRG1 expression and increased neuronal connectivity o Other APs did nto but could be dosing needs optimisation" - Data support idea of CZ model where many different combinations of gene dysfunction may disrupt the key pathways affected in SCZ. Increase number of hiPSC cases and see consistent genes affected, and essential pathways will come to light

Bernnand 2011

Demhaja et al 2014

Kim et al 2021

* Designed behavioural sensory detection task in mice * Given tones embedded in white noise. Would poke a port if signal was there and another if it wasnt. Given water reward * Their confidence in the choices determined by time investments of nose in a given hole * Hallucination = high confidence false alarm * Hallucination-like percepts in mice increased with 1) ketas

Schmack et al 2021

Bitopertin

glycine reuptake inhibitor – 2014 RCT caused improvement of negative symtpoms. However, Roche reported failed endponts in 2 phase III trials in 2014 and it was discontinued

i.Yilmaz 2021

Yoshimizu et al 2015

i.used iPSCs to look at functional phenotype associated with an SNP identified in GWAS Generated iPSCs with the allele and without Found higher expression of CACNA1C in those carrying, confirmed by higher VGCC in those carrying by whole cell recording Although iPSCs not same as in vivo

Lintunen 2021

longitudinal prospective study showed patients on calcium channel blockers had reduction in scz rehopsitalisation (although concomitant AP was allowed)

Karunakaran 2019 (Nature)

was all computational analysis Identified the protein-protein interactions (interactome) of scz associated genes. Looked at which drugs target the interactome and whether they show anticorrelation with the transcriptomic signature seen in the disease (transcriptomics) Identified a shortlist of 12 potential drugs (top 3 were cromoglicic acid, acetazolamide and cinnarizine). No actual screening to see if such drugs alter scz phenotypes – could have done animal model for each repurposed drugs